Streetbeat News

GBIO

Generation Bio Co.

Industry

Biotechnology

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Open

1.32

Mkt cap

92M

Volume

327K

High

1.48

P/E Ratio

-0.63

52-wk high

4.65

Low

1.30

Div yield

N/A

52-wk low

1.10

Generation Bio reported Q1 2024 adjusted EPS of $(1.12), missing the $(0.41) estimate, but their sales of $4.059M exceeded the $1.920M estimate.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 8:22 pm

Generation Bio has announced the acceptance of five abstracts and an invited oral presentation at the ASGCT 27th Annual Meeting, highlighting its research advancements.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 9:35 pm

Needham analyst Gil Blum has reiterated a Buy rating on Generation Bio (NASDAQ:GBIO) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 10:24 am

Wedbush analyst David Nierengarten reiterates an Outperform rating on Generation Bio (NASDAQ:GBIO) and maintains a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 1:18 pm

Needham analyst Gil Blum maintains a Buy rating on Generation Bio (NASDAQ:GBIO) but lowers the price target from $14 to $10.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 11:46 am

Generation Bio (NASDAQ:GBIO) reported Q4 losses of $(0.53) per share, missing the consensus estimate of $(0.45) by 17.78%. This represents a slight improvement over the previous year's loss of $(0.55) per share.

Portfolio Pulse from Happy Mohamed

March 06, 2024 | 9:40 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. NexImmune (NEXI) saw a dramatic increase of 540.4%, while Generation Bio (GBIO) and Altimmune (ALT) also posted substantial gains. Conversely, Ampio Pharmaceuticals (AMPE) and Intelligent Bio Solutions (INBS) were among the biggest losers, with sharp declines in their stock prices.

Portfolio Pulse from Benzinga Insights

December 01, 2023 | 5:31 pm

Generation Bio has announced its intention to continue developing ctLNP for immune cells in collaboration with Moderna. Additionally, Generation Bio plans to develop iqDNA for its lead Hemophilia A and other programs.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:01 pm

Generation Bio Co. announced a strategic reorganization that will result in a 40% reduction of its workforce. This move is aimed at extending the company's cash runway and focusing resources on its most promising programs. The company is prioritizing its efforts on developing its gene therapy platform and advancing its lead programs into the clinic. The reorganization is expected to provide sufficient funds to support operations into 2024.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:00 pm

Wynn Resorts, Limited (NASDAQ:WYNN) shares dropped by 8.1% despite reporting higher than expected third-quarter revenue and earnings per share. The company's revenue was $1.67 billion, surpassing the consensus estimate of $1.585 billion, and adjusted EPS was 99 cents, beating the estimate of 75 cents. The article also lists other stocks that moved in the mid-day session, with various companies experiencing significant gains or losses after reporting their financial results, guidance updates, or other corporate actions.

Portfolio Pulse from Lisa Levin

November 10, 2023 | 6:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.